Evidence Hub

Correction of Tricuspid Regurgitation in Pulmonary Arterial Hypertension

Orlando A, Vergara A, Naeije R, D'Alto M

JACC. Case reports, 2025

1 citation

Abstract

BACKGROUND: Pulmonary hypertension is a contraindication to correction of tricuspid regurgitation.

CASE SUMMARY: A 75-year-old Italian woman with previous episodes of right heart failure was diagnosed with World Health Organization (WHO) functional class IV pulmonary arterial hypertension (PAH) complicated by torrential tricuspid regurgitation. After 6 months of treatment with diuretic agents, macitentan, and tadalafil, she improved to WHO functional class III, with a pulmonary vascular resistance (PVR) decreasing from 5.4 to 3 Wood units. She then underwent transcatheter valve repair. One year later, she was in WHO functional class I with a PVR of 2.2 Wood units.

DISCUSSION: Right heart failure with a moderate increase in PVR in PAH may be caused by severe tricuspid insufficiency. Transtricuspid valve repair under optimized medical treatment may then be successful.

TAKE-HOME MESSAGE: Severe tricuspid regurgitation in PAH may be the dominant cause of right heart failure and is amenable to transcatheter repair under optimal medical therapy.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free